Author Archives: Chandra Ganegoda

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data 55% of BriaCell patients[1] ...

BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq Rules

Philadelphia & Vancouver, British Columbia – October 1, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with ...

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient – quadruple the ...

BriaCell Presents Clinical Efficacy Data at ASCO 2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ ...

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS(TM) in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (NASDAQ: ...

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, ...

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients ...

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...